Based on the Fagron NV stock forecast from 0 analysts, the average analyst target price for Fagron NV is not available over the next 12 months. Fagron NV’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Fagron NV is Slightly Bullish , which is based on 6 positive signals and 5 negative signals. At the last closing, Fagron NV’s stock price was EUR 16.66. Fagron NV’s stock price has changed by -8.76% over the past week, -10.53% over the past month and -0.36% over the last year.
No recent analyst target price found for Fagron NV
No recent average analyst rating found for Fagron NV
Company Overview Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium. Read Less
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and fo...Read More
Frequently Asked Questions About Fagron NV (4A5:F) Stock
Stock Target Advisor's fundamental analysis for Fagron NV's stock is Slightly Bullish .
4A5:F stock's dividend yield is 1.67%.
Our analysis grades 4A5:F stock's dividend yield at F. This means that 4A5:F stock's dividend yield is above 30% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this 4A5:F may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4A5:F's stock to indicate what its average analyst target is.
4A5:F stock's Price/Earning ratio is 16.80.
Our analysis grades 4A5:F stock's Price / Earning ratio at F. This means that 4A5:F stock's Price/Earning ratio is above 43.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this 4A5:F may be fairly valued for its sector
The last closing price of 4A5:F's stock was EUR 16.66.
The most recent market capitalization for 4A5:F is EUR 1.32B.
Unfortunately we do not have enough analyst data on 4A5:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Fagron NV's stock.
As per our most recent records Fagron NV has 3,647 Employees.
Fagron NV's registered address is Venecoweg 20A, Nazareth, Belgium, 9810.
You can get more information about it from Fagron NV's website at https://www.fagron.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Fagron NV (4A5:F) Stock
Stock Target Advisor's fundamental analysis for Fagron NV's stock is Slightly Bullish .
4A5:F stock's dividend yield is 1.67%.
Our analysis grades 4A5:F stock's dividend yield at F. This means that 4A5:F stock's dividend yield is above 30% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this 4A5:F may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4A5:F's stock to indicate what its average analyst target is.
4A5:F stock's Price/Earning ratio is 16.80.
Our analysis grades 4A5:F stock's Price / Earning ratio at F. This means that 4A5:F stock's Price/Earning ratio is above 43.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the F exchange.
Based on this 4A5:F may be fairly valued for its sector
The last closing price of 4A5:F's stock was EUR 16.66.
The most recent market capitalization for 4A5:F is EUR 1.32B.
Unfortunately we do not have enough analyst data on 4A5:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Fagron NV's stock.
As per our most recent records Fagron NV has 3,647 Employees.
Fagron NV's registered address is Venecoweg 20A, Nazareth, Belgium, 9810.
You can get more information about it from Fagron NV's website at https://www.fagron.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4A5:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
